Sanguine BioSciences

Based in the US, Sanguine BioSciences, Inc. is a biotech company specializing in the collection and distribution of biospecimens for research in immunology, oncology, and rare diseases. Sanguine BioSciences, Inc. operates in the biotechnology sector, focusing on biospecimen collection.

Founded in 2010 in Woburn, US, the company has successfully completed 6 deals, with the most recent funding round being a Venture Debt of USD 10. 00 mn from Catalio Capital Management on October 31, 2023. The total amount raised by the company is USD 5. 53 mn.

The company is led by CEO Brian Neman, one of the founders, along with Chérifa Hamida, Nick Houghton, Raaj Sanghvi, and Raphael Stone. Sanguine BioSciences specializes in the collection and distribution of biospecimens, including peripheral blood mononuclear cells (PBMCs), leukopaks, serum, plasma, and whole blood, sourced from a diverse donor population. The company uses a direct-to-donor model enabling individuals to participate in research while meeting researchers' sample requirements across immunology, oncology, and rare diseases. They provide high-quality biospecimens critical for clinical studies and therapeutic development, particularly focusing on conditions such as systemic lupus erythematosus (SLE) and multiple sclerosis.

Sanguine BioSciences generates revenue through direct sales of biospecimen products and services, partnered with research institutions, pharmaceutical companies, and biotech firms. Their transactions often involve customized biospecimen collections tailored to specific research needs. Revenue is accrued from the sale of individual biospecimens and related services, including comprehensive donor data and sample processing, with flagship products like LeukoCore™ leukopaks and PBMC collections being integral to their portfolio. In October 2023, Sanguine BioSciences, Inc.

raised USD 10 mn in venture debt from Catalio Capital Management. The company plans to utilize this funding to accelerate business growth and expansion. While specific new products are not detailed, the focus will include potential developments in their biospecimen offerings and a strategy for entering new geographic regions to enhance their market presence.